(Q36486780)

14 August 2017

1 reference

title

Targeting the ERK signaling pathway in cancer therapy (English)

1 reference

14 August 2017

2

Jacques Pouyssegur

1 reference

14 August 2017

Michiaki Kohno

1

1 reference

PubMed ID

16720434

14 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

38

1 reference

14 August 2017

200-211

1 reference

14 August 2017

3

1 reference

Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation

14 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Pharmacological inhibitors of MAPK pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Epidermal growth factor receptor dependence in human tumors: more than just expression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Ras family signaling: therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

21 January 2018

MAP kinase phosphatases

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Modulation of signalling by Sprouty: a developing story

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

How MAP kinases are regulated

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Gefitinib--a novel targeted approach to treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Cell migration: a physically integrated molecular process

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Role of MAP kinase in tumor progression and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Regulation of cell motility by mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Transcriptional regulation of the Vascular Endothelial Growth Factor gene--a concert of activating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

V599EB-RAF is an oncogene in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

A synthetic inhibitor of the mitogen-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Integrin signalling during tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

Multiple connections link FAK to cell motility and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890600551037

10.1080/07853890600551037

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16720434